Swedish drug developer Karolinska Development has appointed current board member Klaus Wilgenbus as chief executive on an interim basis, following the departure of Torbjörn Bjerke from the position. 30 September 2014
Oncology drug development company focused on antibody drug conjugates targeting major cancers, ADC Therapeutics, has expanded its team significantly as the company’s first antibody drug conjugates enter clinical development. 30 September 2014
UK respiratory specialist Verona Pharma has appointed Biresh Roy as chief financial officer and member of the board of directors, taking over from Richard Bungay. 30 September 2014
Intellectual Property can be vital for the success of any pharmaceutical invention. It is very important to protect your ideas, inventions and creations to prevent them being stolen or copied. 29 September 2014
Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined, according to the firm’s UK marketing director Chris Boulton. Speaking to The Pharma Letter at the impressive AstraZeneca stand at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting in Vienna last week, Mr Boulton said that AstraZeneca is fighting to be at the forefront of the global race to treat diabetes. 29 September 2014
Israeli pharma company Protalix BioTherapeutics has appointed Moshe Manor as its new president and chief executive, effective from November 2. 29 September 2014
UK pharma giant GlaxoSmithKline this morning confirmed recent rumors, saying that Sir Philip Hampton will join the company’s board as non-executive director from January 1, 2015, and will become deputy chairman with effect from April 1, 2015. 25 September 2014
Inflammation, oncology and biodefense biopharma company Soligenix has announced the appointment of Rasappa Arumugham as vice president of biopharmaceutical development. 23 September 2014
Swiss-based iron deficiency specialist Vifor Pharma has appointed Dario Eklund as head of international business operations, and Abdul Mullick as head of global marketing, at its headquarters in Zurich. 19 September 2014
Pharmaceutical companies have widely adopted strategies to outsource elements of their business operations, as part of an ongoing drive to deliver a more flexible model that unlocks cost efficiencies and alleviates some aspects of risk associated with drug development. Recruiting talent is one such element. However, pharma companies should be wary of saving on recruitment at the risk of missing out on the best candidates, particularly when it comes to senior staff. Director of Interims of RSA, Dafydd Wright explains. 19 September 2014
Tim White is head of global customer interaction at Lundbeck. The Pharma Letter spoke to him at the EyeForPharma Multichannel Marketing Summit about how his role can be integrated into research and development, and what part digital marketing can play in the modern pharma landscape. 19 September 2014
The board of partners of Germany’s Merck KGaA has promoted Stefan Oschmann to the position of deputy chief executive and Vice Chairman of the Executive Board. 18 September 2014
USA-based PTC Therapeutics is to expand its global presence by adding key executives to leadership positions in the global commercial team and establishing its international headquarters in Dublin, Ireland. 17 September 2014
Dimension Therapeutics, a US gene therapy company focused on rare diseases, has appointed Annalisa Jenkins as chief executive, who succeeds interim chief executive Thomas Beck. 17 September 2014
Oliver Siegel has been appointed as chief operating officer at Austrian vaccine specialist AFFiRiS AG, where he will take responsibility for business development, finance and administration. 9 September 2014
Swedish drug developer Karolinska Development has appointed Bruno Lucidi as chief executive of the wholly-owned subsidiary KDev Oncology, and portfolio companies Aprea and Akinion Pharmaceuticals. 8 September 2014
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024